Saul B. Helman

VCARD
CV
 

Saul B. Helman, M.D., MBA

Dr. Saul B. Helman is President of Epsilon Life Sciences. He specializes in risk management, compliance, monitorships, litigation and investigations, bringing over two decades of life sciences experience, both in management roles and consulting, to complex client needs.

Saul spends most of his professional consulting time providing support in investigations, litigation, compliance monitorships and compliance integration matters involving life sciences companies. Applying his knowledge secured through working in international marketing and clinical development in industry, Saul has led projects involving expert witness testimony, litigation support, compliance implementation and assessment and investigation support. He has led the support of clients and external counsel with investigations of fraud and abuse in the industry.

Saul's experience includes the development and implementation of global healthcare compliance programs, support of clients through Deferred Prosecution Agreements and Corporate Integrity Agreements, Pre-IRO support, Board and Executive level support through compliance program implementation or evaluation, auditing and monitoring of healthcare compliance programs, support of outside counsel through complex litigation matters including off-label promotion, clinical data management and disclosure, fraud and abuse (False Claims Act, Anti-Kickback Statute and Foreign Corrupt Practices Act) and aggregate spend reporting (Physician Payment Sunshine Act). In addition, Saul has conducted risk assessments and remediation of manufacturing, regulatory, clinical, marketing and sales departments.

Prior to his consulting career, Saul has led a number of organizations across the healthcare continuum, including a global medical staffing organization in the United Kingdom, a home health/home infusion/durable medical equipment/prosthetics and orthotics company in Indiana, and running a rural healthcare clinic in South Africa. He has also led the global launch of pharmaceuticals, international new product planning and various therapeutic area strategies in the bio-pharmaceutical industry.

Saul holds an MBBCh (M.D.) and Bachelor of Science from the University of the Witwatersrand and an MBA from Oxford Brookes University. Saul serves on the Board of The Peace Learning Center.


Highlights from the 23rd Annual Pharmaceutical and Medical Device Ethics and Compliance Congress
Highlights from the 20th Annual Pharmaceutical Compliance Congress
Unveiling the Bittersweet Truth: Cookies, Pixels, and Privacy on the Web
A Reminder on Compliance Considerations in Medical Affairs
Top Ten Takeaways from the 2024 Pharmaceutical Compliance Congress
Top 10 Takeaways from the 25th Annual Pharmaceutical and Medical Device Ethics and Compliance Congress
SIUU Guidance Finalized – What Should We Do?
Top Five Takeaways from the 2025 Pharmaceutical Compliance Congress
How User-Friendly and Effective Are Your Written Standards?
Department of Justice’s September 2024 Update to Evaluation of Corporate Compliance Programs
Carrots for Compliance: Designing Incentives That Drive Success
Changes to FCPA Enforcement – What Do the Tea Leaves Tell Us?
PCF 2025 Key Takeaways - Enforcement Trends
 
Dominica Chadafull